Microvascular invasion (MVI) is strongly associated with the prognosis of patients with hepatocellular carcinoma (HCC). To evaluate the value of Transformer models with Sonazoid contrast-enhanced ultrasound (CEUS) in the preoperative prediction of MVI. This retrospective study included 164 HCC patients. Deep learning features and radiomic features were extracted from arterial and Kupffer phase images, alongside the collection of clinicopathological parameters. Normality was assessed using the Shapiro-Wilk test. The Mann‒Whitney U-test and least absolute shrinkage and selection operator algorithm were applied to screen features. Transformer, radiomic, and clinical prediction models for MVI were constructed with logistic regression. Repeated random splits followed a 7:3 ratio, with model performance evaluated over 50 iterations. The area under the receiver operating characteristic curve (AUC, 95% confidence interval [CI]), sensitivity, specificity, accuracy, positive predictive value (PPV), negative predictive value (NPV), decision curve, and calibration curve were used to evaluate the performance of the models. The DeLong test was applied to compare performance between models. The Bonferroni method was used to control type I error rates arising from multiple comparisons. A two-sided p-value of < 0.05 was considered statistically significant. In the training set, the diagnostic performance of the arterial-phase Transformer (AT) and Kupffer-phase Transformer (KT) models were better than that of the radiomic and clinical (Clin) models (p < 0.0001). In the validation set, both the AT and KT models outperformed the radiomic and Clin models in terms of diagnostic performance (p < 0.05). The AUC (95% CI) for the AT model was 0.821 (0.72-0.925) with an accuracy of 80.0%, and the KT model was 0.859 (0.766-0.977) with an accuracy of 70.0%. Logistic regression analysis indicated that tumor size (p = 0.016) and alpha-fetoprotein (AFP) (p = 0.046) were independent predictors of MVI. Transformer models using Sonazoid CEUS have potential for effectively identifying MVI-positive patients preoperatively.

The study aimed to develop machine learning (ML) models for pretherapy prediction of absorbed doses (ADs) in kidneys and tumoral lesions for metastatic castration-resistant prostate cancer (mCRPC) patients undergoing [¹⁷⁷Lu]Lu-PSMA-617 (Lu-PSMA) radioligand therapy (RLT). By leveraging radiomic features (RFs) from [⁶⁸Ga]Ga-PSMA-11 (Ga-PSMA) PET/CT scans and clinical biomarkers (CBs), the approach has the potential to improve patient selection and tailor dosimetry-guided therapy. Twenty patients with mCRPC underwent Ga-PSMA PET/CT scans prior to the administration of an initial 6.8±0.4 GBq dose of the first Lu-PSMA RLT cycle. Post-therapy dosimetry involved sequential scintigraphy imaging at approximately 4, 48, and 72 h, along with a SPECT/CT image at around 48 h, to calculate time-integrated activity (TIA) coefficients. Monte Carlo (MC) simulations, leveraging the Geant4 application for tomographic emission (GATE) toolkit, were employed to derive ADs. The ML models were trained using pretherapy RFs from Ga-PSMA PET/CT and CBs as input, while the ADs in kidneys and lesions (n=130), determined using MC simulations from scintigraphy and SPECT imaging, served as the ground truth. Model performance was assessed through leave-one-out cross-validation (LOOCV), with evaluation metrics including R² and root mean squared error (RMSE). The mean delivered ADs were 0.88 ± 0.34 Gy/GBq for kidneys and 2.36 ± 2.10 Gy/GBq for lesions. Combining CBs with the best RFs produced optimal results: the extra trees regressor (ETR) was the best ML model for predicting kidney ADs, achieving an RMSE of 0.11 Gy/GBq and an R² of 0.87. For lesion ADs, the gradient boosting regressor (GBR) performed best, with an RMSE of 1.04 Gy/GBq and an R² of 0.77. Integrating pretherapy Ga-PSMA PET/CT RFs with CBs shows potential in predicting ADs in RLT. To personalize treatment planning and enhance patient stratification, it is crucial to validate these preliminary findings with a larger sample size and an independent cohort.

Prostate cancer is one of the most common and lethal cancers among men, making its early detection critically important. Although ultrasound imaging offers greater accessibility and cost-effectiveness compared to MRI, traditional transrectal ultrasound methods suffer from low sensitivity, especially in detecting anteriorly located tumors. Ultrasound computed tomography provides quantitative tissue characterization, but its clinical implementation faces significant challenges, particularly under anatomically constrained limited-angle acquisition conditions specific to prostate imaging. To address these unmet needs, we introduce OpenPros, the first large-scale benchmark dataset explicitly developed for limited-view prostate USCT. Our dataset includes over 280,000 paired samples of realistic 2D speed-of-sound (SOS) phantoms and corresponding ultrasound full-waveform data, generated from anatomically accurate 3D digital prostate models derived from real clinical MRI/CT scans and ex vivo ultrasound measurements, annotated by medical experts. Simulations are conducted under clinically realistic configurations using advanced finite-difference time-domain and Runge-Kutta acoustic wave solvers, both provided as open-source components. Through comprehensive baseline experiments, we demonstrate that state-of-the-art deep learning methods surpass traditional physics-based approaches in both inference efficiency and reconstruction accuracy. Nevertheless, current deep learning models still fall short of delivering clinically acceptable high-resolution images with sufficient accuracy. By publicly releasing OpenPros, we aim to encourage the development of advanced machine learning algorithms capable of bridging this performance gap and producing clinically usable, high-resolution, and highly accurate prostate ultrasound images. The dataset is publicly accessible at https://open-pros.github.io/.

Artificial intelligence (AI) is transforming medical imaging, with large language models such as ChatGPT-4 emerging as potential tools for automated image interpretation. While AI-driven radiomics has shown promise in diagnostic imaging, the efficacy of ChatGPT-4 in liver ultrasound analysis remains largely unexamined. This study evaluates the capability of ChatGPT-4 in liver ultrasound radiomics, specifically its ability to differentiate fibrosis, steatosis, and normal liver tissue, compared to conventional image analysis software. Seventy grayscale ultrasound images from a preclinical liver disease model, including fibrosis (n=31), fatty liver (n=18), and normal liver (n=21), were analyzed. ChatGPT-4 extracted texture features, which were compared to those obtained using Interactive Data Language (IDL), a traditional image analysis software. One-way ANOVA was used to identify statistically significant features differentiating liver conditions, and logistic regression models were employed to assess diagnostic performance. ChatGPT-4 extracted nine key textural features-echo intensity, heterogeneity, skewness, kurtosis, contrast, homogeneity, dissimilarity, angular second moment, and entropy-all of which significantly differed across liver conditions (p < 0.05). Among individual features, echo intensity achieved the highest F1-score (0.85). When combined, ChatGPT-4 attained 76% accuracy and 83% sensitivity in classifying liver disease. ROC analysis demonstrated strong discriminatory performance, with AUC values of 0.75 for fibrosis, 0.87 for normal liver, and 0.97 for steatosis. Compared to Interactive Data Language (IDL) image analysis software, ChatGPT-4 exhibited slightly lower sensitivity (0.83 vs. 0.89) but showed moderate correlation (R = 0.68, p < 0.0001) with IDL-derived features. However, it significantly outperformed IDL in processing efficiency, reducing analysis time by 40%, highlighting its potential for high throughput radiomic analysis. Despite slightly lower sensitivity than IDL, ChatGPT-4 demonstrated high feasibility for ultrasound radiomics, offering faster processing, high-throughput analysis, and automated multi-image evaluation. These findings support its potential integration into AI-driven imaging workflows, with further refinements needed to enhance feature reproducibility and diagnostic accuracy.

Lymphovascular invasion significantly impacts the prognosis of urothelial carcinoma of the bladder. Traditional lymphovascular invasion detection methods are time-consuming and costly. This study aims to develop a deep learning-based model to preoperatively predict lymphovascular invasion status in urothelial carcinoma of bladder using CT images. Data and CT images of 577 patients across four medical centers were retrospectively collected. The largest tumor slices from the transverse, coronal, and sagittal planes were selected and used to train CNN models (InceptionV3, DenseNet121, ResNet18, ResNet34, ResNet50, and VGG11). Deep learning features were extracted and visualized using Grad-CAM. Principal Component Analysis reduced features to 64. Using the extracted features, Decision Tree, XGBoost, and LightGBM models were trained with 5-fold cross-validation and ensembled in a stacking model. Clinical risk factors were identified through logistic regression analyses and combined with DL scores to enhance lymphovascular invasion prediction accuracy. The ResNet50-based model achieved an AUC of 0.818 in the validation set and 0.708 in the testing set. The combined model showed an AUC of 0.794 in the validation set and 0.767 in the testing set, demonstrating robust performance across diverse data. We developed a robust radiomics model based on deep learning features from CT images to preoperatively predict lymphovascular invasion status in urothelial carcinoma of the bladder. This model offers a non-invasive, cost-effective tool to assist clinicians in personalized treatment planning. We developed a robust radiomics model based on deep learning features from CT images to preoperatively predict lymphovascular invasion status in urothelial carcinoma of the bladder. We developed a deep learning feature-based stacking model to predict lymphovascular invasion in urothelial carcinoma of the bladder patients using CT. Max cross sections from three dimensions of the CT image are used to train the CNN model. We made comparisons across six CNN networks, including ResNet50.

High-grade clear cell renal cell carcinoma (ccRCC) is linked to lower survival rates and more aggressive disease progression. This study aims to assess the diagnostic performance of MRI-derived radiomics as a non-invasive approach for pre-operative differentiation of high-grade from low-grade ccRCC. A systematic search was conducted across PubMed, Scopus, and Embase. Quality assessment was performed using QUADAS-2 and METRICS. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the curve (AUC) were estimated using a bivariate model. Separate meta-analyses were conducted for radiomics models and combined models, where the latter integrated clinical and radiological features with radiomics. Subgroup analysis was performed to identify potential sources of heterogeneity. Sensitivity analysis was conducted to identify potential outliers. A total of 15 studies comprising 2,265 patients were included, with seven and six studies contributing to the meta-analysis of radiomics and combined models, respectively. The pooled estimates of the radiomics model were as follows: sensitivity, 0.78; specificity, 0.84; PLR, 4.17; NLR, 0.28; DOR, 17.34; and AUC, 0.84. For the combined model, the pooled sensitivity, specificity, PLR, NLR, DOR, and AUC were 0.87, 0.81, 3.78, 0.21, 28.57, and 0.90, respectively. Radiomics models trained on smaller cohorts exhibited a significantly higher pooled specificity and PLR than those trained on larger cohorts. Also, radiomics models based on single-user segmentation demonstrated a significantly higher pooled specificity compared to multi-user segmentation. Radiomics has demonstrated potential as a non-invasive tool for grading ccRCC, with combined models achieving superior performance.

Enteral feeding needs secure access to the upper gastrointestinal tract, an evaluation of the gastric function to detect gastrointestinal intolerance, and a nutritional target to reach the patient's needs. Only in the last decades has progress been accomplished in techniques allowing an appropriate placement of the nasogastric tube, mainly reducing pulmonary complications. These techniques include point-of-care ultrasound (POCUS), electromagnetic sensors, real-time video-assisted placement, impedance sensors, and virtual reality. Again, POCUS is the most accessible tool available to evaluate gastric emptying, with antrum echo density measurement. Automatic measurements of gastric antrum content supported by deep learning algorithms and electric impedance provide gastric volume. Intragastric balloons can evaluate motility. Finally, advanced technologies have been tested to improve nutritional intake: Stimulation of the esophagus mucosa inducing contraction mimicking a contraction wave that may improve enteral nutrition efficacy, impedance sensors to detect gastric reflux and modulate the rate of feeding accordingly have been clinically evaluated. Use of electronic health records integrating nutritional needs, target, and administration is recommended.

This study aimed to develop and validate a clinical-radiomics deep learning (DL) model based on MRI for endometrial cancer (EC) molecular subtypes classification. This multicenter retrospective study included EC patients undergoing surgery, MRI, and molecular pathology diagnosis across three institutions from January 2020 to March 2024. Patients were divided into training, internal, and external validation cohorts. A total of 386 handcrafted radiomics features were extracted from each MR sequence, and MoCo-v2 was employed for contrastive self-supervised learning to extract 2048 DL features per patient. Feature selection integrated selected features into 12 machine learning methods. Model performance was evaluated with the AUC. A total of 526 patients were included (mean age, 55.01 ± 11.07). The radiomics model and clinical model demonstrated comparable performance across the internal and external validation cohorts, with macro-average AUCs of 0.70 vs 0.69 and 0.70 vs 0.67 (p = 0.51), respectively. The radiomics DL model, compared to the radiomics model, improved AUCs for POLEmut (0.68 vs 0.79), NSMP (0.71 vs 0.74), and p53abn (0.76 vs 0.78) in the internal validation (p = 0.08). The clinical-radiomics DL Model outperformed both the clinical model and radiomics DL model (macro-average AUC = 0.79 vs 0.69 and 0.73, in the internal validation [p = 0.02], 0.74 vs 0.67 and 0.69 in the external validation [p = 0.04]). The clinical-radiomics DL model based on MRI effectively distinguished EC molecular subtypes and demonstrated strong potential, with robust validation across multiple centers. Future research should explore larger datasets to further uncover DL's potential. Our clinical-radiomics DL model based on MRI has the potential to distinguish EC molecular subtypes. This insight aids in guiding clinicians in tailoring individualized treatments for EC patients. Accurate classification of EC molecular subtypes is crucial for prognostic risk assessment. The clinical-radiomics DL model outperformed both the clinical model and the radiomics DL model. The MRI features exhibited better diagnostic performance for POLEmut and p53abn.

Chemotherapy administration is a balancing act between giving enough to achieve the desired tumour response while limiting adverse effects. Chemotherapy dosing is based on body surface area (BSA). Emerging evidence suggests body composition plays a crucial role in the pharmacokinetic and pharmacodynamic profile of cytotoxic agents and could inform optimal dosing. This study aims to assess how lumbosacral body composition influences adverse events in patients receiving neoadjuvant chemotherapy for rectal cancer. A retrospective study (February 2013 to March 2023) examined the impact of body composition on neoadjuvant treatment outcomes for rectal cancer patients. Staging CT scans were analysed using a validated AI model to measure lumbosacral skeletal muscle (SM), intramuscular adipose tissue (IMAT), visceral adipose tissue (VAT), and subcutaneous adipose tissue volume and density. Multivariate analyses explored the relationship between body composition and chemotherapy outcomes. 242 patients were included (164 males, 78 Females), median age 63.4 years. Chemotherapy dose reductions occurred more frequently in females (26.9% vs. 15.9%, p = 0.042) and in females with greater VAT density (-82.7 vs. -89.1, p = 0.007) and SM: IMAT + VAT volume ratio (1.99 vs. 1.36, p = 0.042). BSA was a poor predictor of dose reduction (AUC 0.397, sensitivity 38%, specificity 60%) for female patients, whereas the SM: IMAT + VAT volume ratio (AUC 0.651, sensitivity 76%, specificity 61%) and VAT density (AUC 0.699, sensitivity 57%, specificity 74%) showed greater predictive ability. Body composition didn't influence dose adjustment of male patients. Lumbosacral body composition outperformed BSA in predicting adverse events in female patients with rectal cancer undergoing neoadjuvant chemotherapy.

Accurate and fully automated pancreas segmentation is critical for advancing imaging biomarkers in early pancreatic cancer detection and for biomarker discovery in endocrine and exocrine pancreatic diseases. We developed and evaluated a deep learning (DL)-based convolutional neural network (CNN) for automated pancreas segmentation using the largest single-institution dataset to date (n = 3031 CTs). Ground truth segmentations were performed by radiologists, which were used to train a 3D nnU-Net model through five-fold cross-validation, generating an ensemble of top-performing models. To assess generalizability, the model was externally validated on the multi-institutional AbdomenCT-1K dataset (n = 585), for which volumetric segmentations were newly generated by expert radiologists and will be made publicly available. In the test subset (n = 452), the CNN achieved a mean Dice Similarity Coefficient (DSC) of 0.94 (SD 0.05), demonstrating high spatial concordance with radiologist-annotated volumes (Concordance Correlation Coefficient [CCC]: 0.95). On the AbdomenCT-1K dataset, the model achieved a DSC of 0.96 (SD 0.04) and a CCC of 0.98, confirming its robustness across diverse imaging conditions. The proposed DL model establishes new performance benchmarks for fully automated pancreas segmentation, offering a scalable and generalizable solution for large-scale imaging biomarker research and clinical translation.